NLS PHARPAR Stock

NLSP

CH1384053976

Market Closed - Nasdaq 23:30:00 16/10/2026 +03			5-day change	1st Jan Change
2.500 ^USD	-12.28%		-17.90%	-67.19%

31/10/25	NLS Pharmaceutics Ltd. and Kadimastem Ltd. announce completion of merger	RE
30/10/25	NLS Pharmaceutics Ltd. and Aexon Labs Announces the Expansion of Their Doxa Platform with the AEX-6xx Series	CI

Analysts' recommendations: NLS PHARPAR

29/07/24	Laidlaw Downgrades NLS Pharmaceutics to Hold From Buy	MT
14/09/23	Maxim Downgrades NLS Pharmaceutics to Hold From Buy	MT
08/12/22	Maxim Upgrades NLS Pharmaceutics to Buy From Hold, Price Target is $4	MT
08/11/22	Maxim Downgrades NLS Pharmaceutics to Hold From Buy	MT
06/09/22	Laidlaw Starts NLS Pharmaceutics at Buy With $6 Price Target	MT

More recommendations

News in other languages: NLS PHARPAR

16/11/24	NLS Pharmaceutics : Amended and Restated Articles of Association Form 6 K
22/10/24	NLS Pharmaceutics : Amended and Restated Articles of Association Form 6 K
14/12/21	Schweizer Unternehmen bevorzugten 2021 Börsengang im Ausland
30/06/21	Résumé des principales informations économiques du mercredi 30 juin 2021
30/06/21	Weitere Schweizer Börsengänge im zweiten Semester erwartet

More news

NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
16/10/26	$2.500	-12.28%	23,099
15/10/26	$2.850	+9.20%	5,893
14/10/26	$2.610	-8.10%	9,299
13/10/26	$2.840	-2.20%	5,416
12/10/26	$2.904	-4.63%	1,153

Delayed Quote Nasdaq

More quotes

Market Cap	3.16M 2.81M 2.61M 2.37M 4.48M 300M 4.55M 31.33M 12.28M 157M 11.87M 11.62M 500M	P/E 2023	-1.85x	P/E 2024	-0.8x
Enterprise Value	1.5M 1.33M 1.23M 1.12M 2.12M 142M 2.15M 14.84M 5.82M 74.21M 5.62M 5.5M 237M	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	-	Yield 2023 *	-	Yield 2024	-

31/10/25	NLS Pharmaceutics Ltd. and Kadimastem Ltd. announce completion of merger	RE
30/10/25	NLS Pharmaceutics Ltd. and Aexon Labs Announces the Expansion of Their Doxa Platform with the AEX-6xx Series	CI
30/10/25	NLS Pharmaceutics AG(NasdaqCM:NLSP) dropped from NASDAQ Composite Index	CI
30/10/25	Kadimastem Ltd completed the acqusiition of NLS Pharmaceutics AG from Magnetic Rock Investment AG, BVF Partners L.P., Lind Global Fund II LP a fund managed by The Lind Partners, LLC, YA II PN, Ltd. a managed by Yorkville Advisors Global LP, Felix Grisard, Ronald Hafner and others in a reverse merger transaction.	CI
29/10/25	NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger	CI
29/10/25	Ronen Twito to Become CEO of NewCelX	CI
29/10/25	Ronen Twito to Become Executive Chairman of NewCelX	CI
29/10/25	Nls pharmaceutics announces 1-for-10 reverse share split and name change in connection with proposed merger with Kadimastem	RE
06/10/25	NLS Pharmaceutics AG Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/09/25	NLS Pharmaceutics shareholders approve merger with Kadimastem and related proposals at extraordinary general meeting	RE
10/09/25	Kadimastem, NLS Pharmaceutics announce effectiveness of SEC registration statement for proposed merger	RE
01/09/25	Swiss stocks - Factors to watch on September 1	RE
29/08/25	NLS Pharmaceutics AG agreed to extend merger agreement termination date with Kadimastem from Aug 31 to Oct 31	RE

11-17	NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute	PR
30/10/25	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger	PR
30/10/25	NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs	PR
22/05/25	NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting	AQ
31/03/25	NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement	AQ

1 year	2.36	17.25
3 years	2.36	327.64
5 years	2.36	1,132
10 years	2.36	2,940

	2023	2024
Net sales	-	-
Net income	-12.17M -10.82M -10.03M -9.12M -17.22M -1.16B -17.49M -121M -47.26M -603M -45.68M -44.71M -1.92B	-1.98M -1.76M -1.63M -1.48M -2.8M -188M -2.85M -19.62M -7.69M -98.1M -7.43M -7.28M -313M
Net Debt	736K 654K 606K 552K 1.04M 69.86M 1.06M 7.29M 2.86M 36.45M 2.76M 2.7M 116M	-1.67M -1.48M -1.37M -1.25M -2.36M -158M -2.39M -16.49M -6.47M -82.48M -6.25M -6.12M -263M

NLS PHARPAR Stock

Stocks

NLSP

CH1384053976

Valuation: NLS PHARPAR

Chart: NLS PHARPAR

Latest news: NLS PHARPAR

Analysts' recommendations: NLS PHARPAR

Press Releases: NLS PHARPAR

News in other languages: NLS PHARPAR

Quotes and Performance

Price Extremes

Financials

Company Profile

Quotes

1 day	-12.28%
Current month	-67.19%
Current year	-67.19%